Objective. To investigate whether periodontitis, characterized by marginal jawbone loss, precedes the onset of symptoms of rheumatoid arthritis (RA) , and to analyze plasma levels of RANKL (a cytokine that is crucial for bone resorption) and anti-citrullinated peptide antibodies (ACPAs) in presymptomatic individuals compared with matched referent controls.
Methods. Marginal jawbone loss was measured on dental radiographs of the premolar/molar regions in the jaws in 176 subjects, 93 of whom subsequently developed RA. Among these participating subjects, 46 had documented radiographs predating symptom onset, and 45 cases could be matched to controls, according to sex, age, and smoking status. Plasma RANKL concentrations were analyzed using enzyme-linked immunosorbent assay. A receiver operating characteristic curve was used to define the cutoff value for RANKL positivity.
Results. Bone loss was significantly greater in presymptomatic subjects classified as never smokers compared with that in controls, and increasing levels of bone loss were associated with a higher risk of the subsequent development of RA (hazard ratio 1.03, 95% confidence interval 1.01-1.05). No association between jawbone loss and RA was observed in smokers. A significantly greater extent of marginal jawbone loss was detected in RANKL-positive presymptomatic subjects, and even more pronounced jawbone loss was observed in those who were positive for both RANKL and ACPA.
Conclusion. Marginal jawbone loss preceded the clinical onset of RA symptoms, but this was observed only in nonsmokers. Moreover, marginal jawbone loss was significantly greater in RANKL-positive presymptomatic subjects compared with RANKL-negative presymptomatic subjects and was highest in presymptomatic subjects positive for both ACPA and RANKL.
Periodontitis and rheumatoid arthritis (RA) are both characterized by chronic inflammation at soft tissue sites, leading to a loss of adjacent bone (1) (2) (3) (4) (5) . In periodontitis, tooth-related bacteria evoke gingival inflammation, which in disease-susceptible individuals may cause a loss of jawbone (5) (6) (7) . Patients with progressive periodontitis have elevated serum levels of C-reactive protein (5, 8) , a finding that supports the hypothesis that periodontal inflammation causes a systemic load in these patients. The mechanisms of induction of RA remain unclear, but autoantibodies and increased concentrations of proinflammatory and antiinflammatory cytokines are known to predate the onset of disease symptoms (9, 10) . Despite their different etiologies, periodontitis and RA share a number of similarities concerning host-mediated pathogenesis, genetics (e.g., manifest as an association with HLA antigens), and environmental risk factors such as smoking (1) (2) (3) 6, 7, 11) . Both diseases lead to significant morbidity; in periodontitis, this ultimately leads to tooth loss and loss of masticatory function, while in RA, there is a loss of joint function and mobility (11) .
The majority of epidemiologic studies have shown that periodontitis and RA are associated (12) (13) (14) (15) (16) (17) (18) (19) , and that treatment of periodontitis in patients with RA reduces joint symptoms (20) , but it is not known how these diseases may be related (11, 21) . A number of mechanisms, including infectious, inflammatory, and genetic traits, have been proposed (11, 21) , but prospective studies on the association between periodontitis and RA are sparse.
Enhanced local bone loss is commonly seen in the vicinity of the inflammatory process in diseases such as RA and periodontitis (22, 23) . During balanced physiologic remodeling, osteoblasts form as much bone as the osteoclasts have resorbed, thereby keeping the bone mass constant. In states of unbalanced bone remodeling, such as periodontitis and RA, bone turnover is characterized by increased formation and activity of osteoclasts and by reduced stimulation of bone formation by osteoblasts, leading to bone loss (6, 22, 23) .
Mature bone-resorbing osteoclasts are formed by fusion of mononuclear progenitor cells derived from myeloid hematopoietic stem cells. The specific cytokine driving osteoclast differentiation is RANKL, which activates the receptor RANK expressed by osteoclast progenitors. RANKL is produced as a membrane-bound or secreted ligand by osteoblasts, fibroblasts, or activated T cells and B cells (23) . The production of RANKL by various cell types is controlled by systemic and local stimuli, including hormones, inflammation mediators, and bacterial products (6, 22, 23) . Moreover, in RA, anti-citrullinated peptide antibodies (ACPAs), e.g., against citrullinated vimentin, have been directly linked to osteoclast differentiation and bone resorption in patients with RA, as shown both in vivo and in vitro (24) . Recently, elevated RANKL levels were shown to be associated with ACPA positivity in patients with early untreated RA, with bone destruction (25) , and with radiologic progression after 2 years in patients with early RA (26) .
The involvement of the RANKL system is well established in the pathogenesis of diseases of bone metabolism, including periodontitis, RA, postmenopausal osteoporosis, and bone malignancies such as multiple myeloma (23, 27) . The RANKL level is increased in the serum of affected individuals, and antibodies directed toward RANKL form part of the treatment regimen in all of these conditions except periodontitis (27) (28) (29) (30) (31) .
Thus, the hypothesis of a link between periodontitis and the development of RA has long been debated, but prospective studies are lacking. The aim of the current study was to assess whether periodontitis, displayed as marginal jawbone loss, precedes the onset of symptoms of RA, and whether plasma RANKL levels are related to jawbone loss in subjects in whom RA subsequently develops.
PATIENTS AND METHODS
Study participants. The present case-control study was nested in a population-based survey of cohorts within the Medical Biobank of Northern Sweden (www.biobank.umu.se/ biobank/nshds/). Study cases with a registered date of symptom onset were identified by coanalyzing the register of the Medical Biobank cohorts with the register of patients attending the Department of Rheumatology at University Hospital, Ume a, and fulfilling the American College of Rheumatology 1987 classification criteria for RA (32) .
RA was diagnosed (including in individuals who had symptoms for <12 months) at the Early Arthritis Clinic at Norrlands University Hospital, Umeå, Sweden, by a senior rheumatologist who carefully monitored the patient-reported date of onset of RA-related symptoms. The time points preceding onset of symptoms are referred to as the "presymptomatic time." The earliest date for joint symptoms was thus defined as the date of symptom onset. The dental radiographs selected for the hazard estimates were obtained well before the identified date of symptom onset (1-7 years preceding symptom onset, as described below). However, no information on joint symptoms was available from the dental records at the time when dental radiographic analyses were performed.
In total, 232 individuals for whom information was available prior to the onset of RA symptoms (referred to as presymptomatic individuals) and 194 matched controls were identified from the register of the Medical Biobank and were alive at the time of this study. Both cases and control subjects were invited, by mail, to participate in the study and were asked to answer a questionnaire on self-assessed dental status, smoking habits, and contact information for their dental clinic. Responses to the questionnaire were obtained from 149 cases (64.2%) and 143 controls (73.7%). Dental radiographs of the premolar/molar regions of the jaw could be obtained from the providers of dental care in 176 of the subjects (Table 1) . Among these identified subjects, 93 were subsequently diagnosed as having RA, and 83 were used as population-based controls.
Of the 93 subjects with presymptomatic RA, 46 had radiographs available before the onset of RA symptoms. Radiographs for the remaining 47 subjects were available only from the same year as symptom onset (n = 2) or later after RA symptom onset. Thus, 46 subjects for whom radiographs were available prior to becoming symptomatic for RA formed the group to which a referent control group, matched for sex, age (AE3 years), and smoking status (never, past, or current smoker), was selected at random, without any replacements. Due to the very low prevalence of current smokers among the potential controls, the final study group comprised 45 cases and 45 matched controls (Table 2 ). In several of these cases and controls, repeated radiographic examinations were also performed after the onset of RA symptoms. In 31 of the 45 case-control pairs, both the case and the matched referent control had undergone a radiographic examination before the onset of symptoms, as well as repeated radiographic examinations for longitudinal evaluation of bone loss after becoming symptomatic and being diagnosed as having RA.
Assessment of bone loss. Bone loss was assessed on bitewing radiographs of the premolar/molar sections of the jaws. Radiographs were obtained from dental offices after the participants had granted their permission. Two films were available per section, ranging from the mesial surface of the first premolar to the distal surface of the second molar. Third molars positioned as a second molar were regarded as second molars. Other types of radiographs, such as apical and panoramic images, were occasionally used to confirm the assessments.
For the presymptomatic individuals (cases), radiographs obtained 1-7 years (mean 3.8 years, 95% confidence interval [95% CI] 3.2-4.4 years) before the symptoms of RA (referred to as year 0) were selected for evaluation of jawbone loss. Radiographs obtained in age-matched individuals without RA were used as controls.
Bone loss was scored as present (score of 1) or not present (score of 0) for each tooth in the examined sections. The presence of bone loss (score of 1) was scored if a reduction in marginal bone level corresponded to more than two-thirds of the height of the tooth crown of the same tooth. This criterion was based on an attachment loss of 3-4 mm, defined by the American Academy of Periodontology as moderately severe periodontitis (33, 34) , and an estimate that, on average, two-thirds of the height of the tooth crown corresponds to 3.7 mm. The latter was defined by measurements of the height of the total tooth crown, i.e., the distance from the cement-enamel junction to the crown ridge in premolars. This distance was on average 5.4 mm, meaning that two-thirds of the height of the crown corresponded to 3.7 mm, i.e., 3-4 mm. Bone loss was assessed by 2 dentists (EK and CKH) who had calibrated their evaluations. Interobserver agreement was evaluated for 20 individual radiographic observations, which yielded a kappa value of 0.91.
One of the following characteristics was noted for each tooth: 1) intact, i.e., the tooth could be assessed in its entirety and showed no sign of bone loss exceeding two-thirds of the length of the tooth crown, 2) bone loss, i.e., the tooth displayed bone loss exceeding two-thirds of the length of the tooth crown at any site, and if the marginal bone level was not captured on the bitewing radiographs (because of severe bone loss), it was also scored as bone loss, 3) missing, i.e., the tooth was missing or a retained root tip was present, or 4) not assessable, i.e., the tooth could not be evaluated.
Total bone loss was defined as the sum of the number of teeth with scored bone loss and lost teeth in proportion to the number of teeth assessable for scoring.
Plasma analysis. Plasma samples from the cases (n = 47) were analyzed for the levels of RANKL before the onset of symptoms, including within the same year as symptom onset, with a median time predating the onset of symptoms of 4.0 years (interquartile range 2.0-7.2 years). Plasma samples from the controls (n = 83) were analyzed when radiographs of the jaws were available for these subjects. The radiographic examinations were * Radiographs of the premolar/molar regions in the jaws of 93 presymptomatic subjects (n = 694 visits) and 83 control subjects in whom rheumatoid arthritis (RA) did not develop (n = 659 visits) were obtained and evaluated for missing teeth and teeth with or without bone loss. 95% CI = 95% confidence interval; min = minimum; max = maximum; anti-CCP-2 = anti-cyclic citrullinated peptide 2; RF = rheumatoid factor; SE = shared epitope. † Mean 6.4 (min-max 0-18) and 4.5 (min-max 0-16) number of radiographic evaluations before and after RA diagnosis, respectively. ‡ The frequency of positivity at the time of RA diagnosis was 74.7%. § The frequency of positivity at the time of RA diagnosis was 78.6%. * The final study group included 45 subjects for whom the marginal jawbone level could be evaluated before the onset of rheumatoid arthritis (RA) symptoms (presymptomatic patients) and a control group matched for sex, age, and smoking status. Total bone loss is defined as the sum of the number of teeth with scored bone loss (teeth that could be evaluated and in which bone loss was evident) and lost teeth (teeth that are missing, possibly due to major bone loss) in proportion to the number of teeth accessible for scoring. 95% CI = 95% confidence interval; min = minimum; max = maximum. † Event refers to RA symptom onset in cases and end of study period in controls. ‡ P = 0.020 versus controls, by Student's t-test. § Mean values were adjusted for sex, age at radiography, year of radiography, smoking status, and dental care provider. ¶ P = 0.017 versus controls.
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KINDSTEDT ET AL selected at a time point that was as close as possible to the date of plasma sampling. Consequently, for these analyses, we were unable to keep the matched pairs, as previously described. The plasma concentration of total (free and bound) RANKL was measured using a RANKL human enzyme-linked immunosorbent assay kit (BioVendor) in accordance with the protocol described by the manufacturer. A cutoff value for RANKL positivity was defined using a receiver operating characteristic curve, yielding a cutoff value for positivity of >0.927 nmoles/liter, with a specificity of 97.9%. Positivity for ACPA, rheumatoid factor (RF), and the HLA shared epitope was analyzed as previously described (26) .
Statistical analysis. Categorical variables, i.e., sex, smoking status at the time of radiographic evaluation (never or ever smoker [past or current]), and dental care provider (public dental clinic, private office, or a combination of public and private), are presented as numbers or proportions (percent). Differences in distribution between the cases and controls were tested by chi-square test.
For continuous, normally distributed variables (i.e., age, birth year, year of radiographic evaluation), mean values with 95% CIs or minimum-maximum values are presented. Differences in group mean values between presymptomatic subjects and referent controls were tested using Student's t-test when values were normally distributed; otherwise, comparisons were performed using nonparametric tests. RANKL concentrations were logarithmically transformed to reach normality. Using the generalized linear model procedure, group mean values for the number of intact teeth and total jawbone loss were standardized for potential confounders, i.e., sex, age at the time of radiographic evaluation, year of radiographic evaluation, smoking status, and dental care provider. In addition, sensitivity analyses with stratification for smoking status, i.e., never smokers and ever smokers, were performed.
Hazard ratios (HRs) (with 95% CIs) for subsequent development of RA according to increasing levels of total jawbone loss were calculated from Cox proportional hazards models, using a time-dependent covariate (age) and adjustment for potential confounders (dental care provider and year of radiographic evaluation). All tests were 2-sided, and P values less than 0.05 were considered significant. SPSS version 23.0 was used for the data analyses.
Ethics approval. This study was approved by the Regional Ethical Review Board at Ume a University (Dnr no. 2013/ 347-31M). Data were collected and analyzed in accordance with the guidelines of the Declaration of Helsinki, including the requirement that written consent be obtained from the participants, and in accordance with the Swedish Personal Data Act.
RESULTS
Study group characteristics. The characteristics of the 176 consenting participants for whom dental records were available are shown in Table 1 . The characteristics of the 45 presymptomatic subjects and their matched referent controls are shown in Table 2 . The proportions of men and women, never smokers and ever smokers, and dental care providers, as well as the mean age and mean birth year, were similar between the subsample of 90 presymptomatic subjects and matched controls and the total sample of 176 subjects.
Comparison of bone loss in presymptomatic subjects and matched controls. The mean number of intact teeth, i.e., teeth with jawbone loss of less than two-thirds of the tooth crown, was significantly lower in presymptomatic subjects compared with matched controls (mean 7.8 versus 9.9; P = 0.02). In addition, the proportion of teeth with jawbone loss in the 45 presymptomatic subjects and their matched controls was significantly higher in those who developed RA symptoms years after the assessment (46.9% versus 32.9%; P = 0.017) ( Table 2) .
Stratification according to smoking status revealed that these differences were seen only in subjects who reported having always been a nonsmoker (Table 3 ). In presymptomatic subjects who never smoked, the mean * Total bone loss is defined as the sum of the number of teeth with scored bone loss (teeth that could be evaluated and in which bone loss was evident) and lost teeth (teeth that are missing, possibly due to major bone loss) in proportion to the number of teeth accessible for scoring. 95% CI = 95% confidence interval; min = minimum; max = maximum. † Mean values were adjusted for sex, age at radiography, year of radiography, and dental care provider. ‡ P = 0.039 versus controls. § P = 0.015 versus controls.
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number of intact teeth was 7.1, compared with a mean of 10.8 intact teeth in the referent controls (P = 0.039). The corresponding values for the mean number of teeth with total bone loss were 52.4 in presymptomatic cases and 26.0 in matched referent controls (P = 0.015). A numerically similar trend was seen in ever smokers (past and current), but differences between the groups were not statistically significant (Table 3) . Following the univariate tests, Cox regression analyses were performed to compare subjects in whom RA symptoms developed with those in whom RA symptoms did not develop for the levels of jawbone loss, in all case-control sets as well as in each smoking stratum ( Table 4 ). The crude model (including total bone loss in those teeth that were accessible for scoring and age) showed positive associations in nonsmokers (HR 1.026, 95% CI 1.005-1.047, P = 0.017). In models additionally adjusted for dental care provider and for year of radiographic evaluation, the HR was not affected, but the 95% CI was wider, and the P value was borderline significant (0.050) ( Table 4) . No association was seen among ever smokers (Table 4) .
Changes in bone loss could be tracked from 4 years before (year -4) up to 6 years after the onset of symptomatic RA in 31 case-referent control sets in which both the presymptomatic subject (case) and the matched referent had radiographs available after the year that the presymptomatic subject developed symptoms of RA (Figure 1 ). The level of jawbone loss at year -4 was standardized to 0, and any bone level alteration was determined for the year of RA symptom onset (year 0), and 3, 5, and 6 years thereafter. Both the presymptomatic subjects and their matched controls displayed increased bone loss over time, but from 5 years onward, the mean loss increment was significantly higher in the presymptomatic subjects (P < 0.05).
Plasma RANKL. In presymptomatic subjects, the median (first quartile, third quartile) RANKL concentration was 0.355 nmoles/liter (0.176, 0.695), whereas the concentration in controls was 0.305 nmoles/liter (0.146, 0.524), but the difference was not significant. Among presymptomatic subjects, 14.9% had levels above the cutoff compared with 6.1% of controls (P = 0.098). RANKL-positive presymptomatic subjects had a significantly greater extent of marginal jawbone loss compared with RANKLnegative presymptomatic subjects (P = 0.031) (Figure 2 ). There was a weak correlation between the RANKL concentration and jawbone loss (r s = 0.296, P = 0.043). These measurements were not significantly different in controls, irrespective of RANKL positivity. There was no association between RF positivity and bone loss in the presymptomatic subjects or controls, although ACPA-positive presymptomatic subjects had higher values for bone loss compared with controls (27.3% and 13.9%, respectively; P < 0.05). The concentration of RANKL was significantly higher in presymptomatic subjects who were positive for either ACPA 0.050 * Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated from Cox proportional hazards models with a time-dependent covariate (age) and adjustment for potential confounders. The crude model included total bone loss as a percent of teeth accessible for evaluation and a time-dependent covariate (age). The adjusted model included total bone loss as a percent of teeth accessible for evaluation, a time-dependent covariate (age), dental care provider, and year of radiographic evaluation. Figure 1 . Mean increase in bone loss in presymptomatic subjects (cases) and matched controls over time. The percent bone loss at year -4 was standardized to 0. The year of rheumatoid arthritis (RA) symptom onset was set to year 0. Increased bone loss 3, 5, and 6 years after RA symptom onset is shown. Group differences calculated after the repeated-measures analysis of variance showed a difference between groups. * = P < 0.05, cases versus controls; *** = P < 0.001.
or RF (P < 0.002 and P < 0.001, respectively). In subjects who were positive for both ACPA and RANKL, bone loss was significantly higher compared with that in subjects in the subgroups (mean AE SEM 53.8 AE 6.4% versus 20.4 AE 5.3% in the subgroup positive for ACPA only, 18.8 AE 10.8% in the subgroup positive for RANKL only, and 13.1 AE 3.2% in the subgroup negative for both ACPA and RANKL; P < 0.016).
DISCUSSION
The current study is, to our knowledge, the first to show that a more severe loss of tooth supporting bone precedes the onset of RA symptoms. This was particularly evident in nonsmoking presymptomatic subjects. Moreover, this study showed that subjects with presymptomatic RA who were RANKL-positive displayed a significantly higher degree of marginal jawbone loss, particularly those who were ACPA-positive.
Although several cross-sectional studies have shown that patients with RA have a higher prevalence of periodontitis compared with individuals with healthy joints (12) (13) (14) (15) (16) (17) (18) (19) , several studies have shown contradictory results (35) (36) (37) . This discrepancy could be due to various reasons, including the use of different disease classifications, cohort sizes, and the notion that treatment of RA could affect periodontal health (13, 37, 38) .
Our finding of increased periodontal jawbone loss before the onset of RA symptoms in patients compared with controls was statistically significant, but the association was modest. This was probably attributable to the low number of individuals for whom radiographs obtained prior to the development of RA symptoms were available. This is a weak point of our study, as was the fact that we were unable to obtain information regarding periodontitis classification and diagnosis and were reliant on the obligate outcome measurement of periodontitis, namely jawbone loss. In a prospective study of periodontal disease and the risk of RA, Arkema et al observed no association between severe periodontitis (as assessed by the history of periodontal surgery and/or tooth loss), and the risk of RA (35) . The different results between the Arkema study and our study could be due to the fact that periodontal surgery is performed only in individuals with severe periodontitis, while estimation of marginal bone loss is a more nuanced measure of the severity of periodontal disease. Patients with arthralgia who were diagnosed as having periodontitis had an increased risk of future treatment with methotrexate as a consequence of a diagnosis of RA (39) , which is consistent with our findings. Further large prospective controlled epidemiologic studies could possibly strengthen the observation that periodontitis precedes RA.
An association between periodontitis and RA has been considered since the early 1820s.The relationship has been intensively debated during the past 2 decades, and several hypotheses regarding pathogenic links have been proposed (11, 21, 38) . Smoking is a common environmental factor associated with both diseases. Consequently, we were able to see bone loss differences only in nonsmokers, which is consistent with the results of a previous study (18) . Genetic factors are driving the host responses in both RA and periodontitis, which could serve as common ground. Periodontitis is primarily an infectious inflammatory condition that progresses to chronic inflammation, thus representing similarities with the inflammatory process in RA (2, 40) . An imbalance between proinflammatory and antiinflammatory cytokines is evident in both RA and periodontitis. Both conditions are associated with soft tissue and bone destruction involving inflammatory cytokines such as interleukin-1, tumor necrosis factor, and prostaglandin E 2 , enzymes such as matrix metalloproteinases, and increased RANKL levels (2, 22, 23) .
In the current study, we observed that marginal jawbone loss was significantly greater in RANKL-positive presymptomatic subjects compared with RANKL-negative presymptomatic subjects. Furthermore, the highest marginal jawbone loss was observed in subjects who were positive for both ACPA and RANKL. The observation that periodontal jawbone loss was more severe in "RApredisposed" RANKL-positive individuals could indicate that there may be a subgroup of presymptomatic individuals who share a pathologic pathway of imbalanced immunoinflammatory bone remodeling with individuals who have severe periodontitis. In this study, it was not possible to determine whether the source of RANKL was periodontitis, and we cannot rule out the possibility that the relationship between RANKL and increased jawbone loss in presymptomatic individuals was associative or causative, but the observation motivates further larger studies. Figure 2 . Bone loss in RANKL-positive presymptomatic subjects (cases) and controls and RANKL-negative cases and controls. Bars show the mean AE SD. NS = not significant. * = P < 0.05; ** = P < 0.01.
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The periodontium not only is a reservoir for cytokines that are released into the circulation but also is a habitat for bacteria. In a sensitive host, a dysbiotic gram-negative flora evokes an inflammatory response in the periodontium. The periodontal pathogen Porphyromonas gingivalis, which expresses the enzyme peptidylarginine deiminase and has the capacity to citrullinate proteins and generate antibodies (e.g., ACPA), has been suggested as a possible link between periodontal infection and RA (11, 41) . Another recently discussed microbial species is Aggregatibacter actinomycetecomitans, which has hypercitrullinating abilities (42) . Periodontitis in patients with RA has been observed, particularly in those who are ACPA-positive and/or RF-positive or have a higher concentration of these antibodies (18, 43) , although this finding has not been confirmed by other groups of investigators (16) . Periodontitis per se has been shown to be related to ACPA (anti-citrullinated a-enolase peptide 1) but also to uncitrullinated peptides of autoantigens in RA (44) . We showed that the combination of positivity for both RANKL and ACPA was related to increased marginal jawbone loss. Because ACPAs have been shown to potentiate RANKL-induced osteoclast formation and bone resorption, it is possible that the high jawbone loss that we observed in RANKL-positive presymptomatic subjects was driven by ACPA.
Our study has some limitations. For example, the cases and controls were identified from a populationbased survey for cardiovascular disease risk factors. In both cases and controls, blood samples were obtained at certain age points, whereas dental radiography was performed at time points that were completely unrelated to the timing of blood withdrawal, which will result in a reduced number of included individuals with data available for subgroup analyses. Because our findings that increased periodontal jawbone loss preceded symptoms of RA are based on the patient's report on symptom onset to the senior rheumatologist and not to the dentist at the time of the oral examination, we are not able to ascertain that radiography, in all cases, was performed in asymptomatic subjects. To decrease the risk of evaluating jawbone loss in symptomatic individuals, radiographs in the defined presymptomatic subjects were selected 1 year preceding the self-reported date of symptom onset. Another limitation is the lack of information on family history of diseases other than cardiovascular diseases and diabetes.
In conclusion, the key finding of this study indicates that in subjects who subsequently developed RA, more pronounced marginal jawbone loss was associated with preexisting periodontitis. Although this association was statistically significant, the relationship was modest.
Moreover, marginal jawbone loss and the plasma RANKL level were related in ACPA-positive presymptomatic subjects. Additional research, with regard to both basic mechanisms as well as clinical studies, are needed to determine whether there is a causative link between periodontitis and RA or whether jawbone loss and RA represent a "2 sides of the same coin" phenomenon.
